Litifilimab

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameLitifilimab
Drug Alias NameBIIB-059
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-C-Type lectin domain family 4 member C
TargetsC-Type lectin domain family 4 member C
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Idec Research LtdRoyalty Pharma PLCBiogen Inc +[5] 
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A